NasdaqGS:ALKSBiotechs
A Look at Alkermes's Valuation Following Promising Vibrance-2 Phase 2 Results for Alixorexton
Alkermes (ALKS) shared positive topline data from its Vibrance-2 phase 2 study evaluating alixorexton in narcolepsy type 2. The study showed clinically meaningful improvements and a generally well-tolerated safety profile.
See our latest analysis for Alkermes.
Alkermes’ positive phase 2 results for alixorexton come after a steady year of pipeline updates and industry presentations, helping drive a 9.2% year-to-date share price return and fueling a sense of renewed momentum. The stock’s 7.4%...